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ABSTRACT
Cockayne syndrome (CS) is a rare progeroid disorder characterized by multisystem degeneration, including neurological dysfunction, for which deep brain stimulation (DBS) is a proposed treatment. This study represents only the third case of DBS for
CS-associated movement disorder and the first in which both proposed targets had devices implanted, allowing for direct comparison. A case of DBS for CS-associated movement disorder is presented. Previous literature documents two cases with one
targeting the ventral intermediate nucleus of the thalamus (VIM) and the other targeting the globus pallidus interna (GPi). Our
patient underwent stimulation of GPi nuclei followed by repositioning to VIM nuclei with improved symptom control using
VIM stimulation. In all cases, there was a significant clinical benefit without off-target effects. CS-associated movement disorder
exhibits phenotypic variability for which DBS is a viable treatment. Target selection should be driven by clinical phenotype.
KeywordsaaCockayne syndrome; Deep brain stimulation; Dystonia; Tremor.

As the use of deep brain stimulation (DBS) in the treatment
of movement disorders continues to expand, there is increasing
interest in its application for rare disorders. Cockayne syndrome
(CS) is a rare progeroid disorder that causes premature aging
of all tissues and is characterized by multisystem degeneration,
including neurological dysfunction.1,2 CS is a disorder of nucleotide excision repair mechanisms, of which there are several other known disorders with overlapping phenotypes, such as xeroderma pigmentosum and trichothiodystrophy.3 CS has many
identified causative genetic mutations that manifest a spectrum
of phenotypic variation, including neurological symptoms.3 Neurological symptoms include medically refractory dystonia and
tremor, which make the application of DBS a promising treatment. We provide only the third documented case utilizing DBS
for the treatment of hyperkinetic movement disorder associated
with CS and review the details of the previous cases for a comparative series.

CASE REPORT
Our patient is a 10-year-old male with CS who presented to
the pediatric neurology clinic for consideration of treatment options, including DBS, for CS-associated movement disorder. The
patient began to show initial symptoms at approximately 12–15
months of age, as he did not begin to walk until 15 months of age.
His parents report frequent stumbling and clumsy movements
with poor coordination, which has been pervasive through his
development. He began to exhibit a tremor at 5 years of age, which
prompted further investigation, including magnetic resonance
imaging of his brain, which revealed imaging characteristics suggestive of CS (Supplementary Figure 1 in the online-only Data
Supplement).1 A physical exam revealed a bilateral high amplitude, low to moderate frequency jerky postural and intention
tremor. Additional clinical criteria consistent with CS were progressive growth failure, microcephaly, cutaneous photosensitivity, and speech delay.1 Genetic testing was pursued, and DNA se-
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quencing confirmed mutations in both copies of ERCC6, a gene
involved in nucleotide excision repair, which is diagnostic of CS.3
Two separate variant mutations (p.Gln156*, p.Tyr1179Leufs*22)
were identified in our patient, both of which matched previously
identified pathogenic mutations.4 There was no family history of
CS and no other known affected family members. Medical therapy for tremor, including gabapentin and primidone, was ineffective; therefore, DBS treatment was discussed with the family,
who elected to proceed with the surgery. The patient subsequently underwent placement of DBS electrodes to the globus pallidus
interna (GPi) nuclei bilaterally in a standard fashion utilizing
the Medtronic Activa DBS platform (Medtronic, Minneapolis,
MN, USA). There are only two prior publications regarding DBS
therapy for CS, with one targeting the GPi and the other targeting the ventral intermediate nucleus of the thalamus (VIM).5,6
GPi was chosen as the initial target, with the idea that it would
address both dystonic and hyperkinetic symptoms.7 Shortly after implantation, the patient experienced an episode of noninfectious perielectrode edema resulting in encephalopathy, a seizure and a 6-day hospitalization. He was treated with high-dose
steroids followed by steroid taper without residual deficits. Once
the patient recovered, programming was initiated with monop-

olar stimulation of contacts 11 and 3 at a frequency of 130 Hz, a
pulse width (PW) of 60 μs, and an amplitude of 1.5 V. The patient noted decreased tripping and a 5-pound weight gain with
these settings but minimal improvement in his tremor, suggesting the treatment had a greater impact on dystonia than tremor
(Table 1). Due to a tremor phenomenology similar to Holmes
tremor,8 programming was adjusted to monopolar stimulation
of posteroventral contacts 8 and 0 at a frequency of 75 Hz, a PW
of 100 μs, and an amplitude of 1.5 V, with some improvement in
tremor control (Table 2).
Five months after the initial implantation, high impedance values were noted bilaterally, prompting a surgical exploration of the
system. During surgery, wire disconnects were noted in both leads
requiring replacement of the intracranial leads. Given the need
to replace the intracranial leads, the decision was made to reposition the electrodes to the bilateral VIM nuclei in hopes of gaining improved tremor control. Surgery was uneventful, and the
patient was discharged home the following day. Programming
of the bilateral VIM was initiated with monopolar stimulation
of contacts 8 and 0 at a frequency of 50 Hz, a PW of 130 μs, and
an amplitude of 1 V (Table 2). This programming was eventually
transitioned to double bipolar stimulation with an increased am-

Table 1. Patient characteristics and DBS treatment response
Age at
onset

Symptoms

Age at DBS
implant

DBS target

Stimulation response

Duration of response

Hebb et al. ,
2006

15 months - Complex hyperkinetic
syndrome
- Severe chorea
- Myoclonus
- Bilateral intention tremor
- Dystonic features

17 years

- Improvements stabilized
VIM (unilateral) - Contralateral chorea,
after first year
myoclonus improved in
- System inadvertently
few days to weeks
- Eventually (with increased deactivated 4 years
postop, no deterioration
amplitude of stimulation)
in clinical symptoms
axial and then ipsilateral
improvements noted
- Intention tremor and
dystonia persisted

Hamasaki
et al.5, 2010

30 years

-C
 ervical dystonia that
progressed to secondary
generalized
- Blepharospasm
- Oromandibular grimacing
- Truncal bending and
torsion
- Dystonic tremor
- Postural instability

52 years

GPi (bilateral)

- Dystonia and dystonic
tremor improved over first
weeks to months
- Axial symptoms did not
improve

- Continued improvements to
5 months with stabilization
at last follow-up

Our patient 1st implant

12–15
months

- Frequent stumbling
-P
 oor coordination with
clumsy movements
- Balance difficulty
- Tremor (started at age 5)

10 years

GPi (bilateral)

- Mild to moderate bilateral
tremor reduction

- High impedance noted after
4 months prompting surgical
exploration
- Opted to move intracranial
leads to bilateral VIM in hopes
of better response

Our patient 2nd implant

Same

Same

11 years

VIM (bilateral)

- Resting tremor resolved
with significant
improvement in intention
tremor

- Continued refinement in
programming with continued
substantial improvement in
tremor control 12 months
postoperatively

6

DBS, deep brain stimulation; VIM, ventral intermediate nucleus of the thalamus; GPi, globus pallidus interna.
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plitude and a lower frequency (10+, 9-, 8-/2+, 1-, 0-, 2.5–3.5 V,
PW 140–160 μs, Freq 20 Hz), which led to improved tremor control. With the VIM target and these programming settings, the
patient had resolution of his resting tremor and significant improvement in his intention tremor, leading to an improvement
in functionality to the point that he was now able to hold his lunch
tray at school and eat meals using utensils without spilling his
food. Video from the initial programming visit is shown with the
patient performing the finger-to-nose task prior to the activation
of the system and then with the initial settings prior to fine-tuning at subsequent visits (Supplementary Video 1 in the onlineonly Data Supplement). Informed consent was obtained from
the patient’s parents for the use of the video in publication.

DISCUSSION
CS-associated movement disorder exhibits phenotypic variability ranging from dystonia-predominant to tremor-predominant subtypes. CS has been described to have several types, with
Type 1 being the classical form, Type 2 being a more severe subtype, and “mild CS” including patients with some clinical features but lacking at least some cardinal features.2 CS 2 is more
severe, with death often occurring by age 6 or 7, while patients
with CS 1 have an average lifespan of 12.3 years, with a proportion surviving into young adulthood.1,2 Given the rarity of CSassociated movement disorder, there is limited experience in its
treatment. The underlying pathology is thought to be secondary to pathologic changes in the basal ganglia thalamocortical
motor loop. Based on the experiences in this series of patients,

DBS is a viable treatment for CS. DBS can be considered for patients with CS who display a more slowly progressing phenotype, as they may have a sufficient lifespan to benefit from the
treatment. In the two previous cases, a patient with a mixed hyperkinetic movement disorder responded to VIM stimulation,
while a patient with dystonia predominance responded to GPi
stimulation.
The first case was described by Hebb et al.,6 in which a 17-yearold male with CS underwent implantation of a DBS electrode
in the VIM nucleus. The patient exhibited a mixed hyperkinetic
movement disorder with severe chorea, myoclonus, bilateral intention tremor, and dystonic features, which continued to progress and were refractory to multiple medications. A unilateral system was implanted targeting the VIM nucleus, and programming
data are described in Table 2. The chorea and myoclonus improved
in the first few days to weeks on the contralateral side; eventually,
with increased stimulation amplitude, axial and ipsilateral improvements were noted (Table 1).
The second case was described by Hamasaki et al.,5 in which a
52-year-old male with CS underwent implantation of DBS electrodes to the bilateral GPi nuclei. The patient had progressive
symptoms primarily manifesting cervical dystonia that later generalized, greatly impairing function. He underwent placement of
bilateral GPi electrodes, and programming data are described in
Table 2. The patient’s cervical dystonia and dystonic tremor improved over the first several weeks with continued improvement
to his last follow-up five months postoperatively. His axial symptoms did not improve; however, he was able to feed himself one
week after surgery, which he could not do preoperatively (Table 1).

Table 2. DBS programming settings
DBS target

Initial programming

Adjustments

Hebb et al. , 2006

VIM (unilateral)

Bipolar stimulation
Contacts: 0, 3
Frequency: 130 Hz
Pulse width: 60 μs
Amplitude: 2 V

Amplitude increased from 2 V gradually up to 3.5 V, 4 V based on
improved axial tremor control

Hamasaki et al.5, 2010

GPi (bilateral)

Monopolar stimulation
Contacts: 0, 1
Frequency: 130 Hz
Pulse width: 450 μs
Amplitude: 2.8 V

Amplitude gradually increased up to 2.8 V over first month; no other
significant changes mentioned

Our patient - 1st implant

GPi (bilateral)

Monopolar stimulation
Contacts: 11, 3
Frequency: 130 Hz
Pulse width: 60 μs
Amplitude 1.5 V

Monopolar stimulation
Contacts: 8, 0
Frequency: 75 Hz
Pulse width: 100 μs
Amplitude: 1.5 V

Our patient - 2nd implant

VIM (bilateral)

Monopolar stimulation
Contacts: 8, 0
Frequency: 50 Hz
Pulse width: 130 μs
Amplitude: 1 V

Bipolar stimulation (double)
Contacts: 10+, 9-, 8-/2+, 1-, 0Frequency: 20 Hz
Pulse width: 140–160 μs
Amplitude: 2.5–3.5 V

6
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In our patient, we had the unique opportunity to evaluate clinical responses to each of the previously utilized targets in CS. He
experienced greater symptom reduction and functional improvement with VIM stimulation as opposed to GPi stimulation. This
may not be completely unexpected given that the patient had
tremor-predominant symptomatology as opposed to dystoniapredominant symptomatology, which may respond better to GPi
stimulation. Additionally, the patient’s physical exam revealed a
bilateral high amplitude, low to moderate frequency jerky postural and intention tremor, consistent with a cerebellar tremor.
On histopathologic analysis, there was notable Purkinje cell degeneration, which is likely a contributing factor in this phenotype in CS.9 In regard to our patient’s GPi stimulation, several potential limiting factors are present that deserve comment. The
first is that there was an episode of noninfectious perielectrode
edema, which is a rare complication of DBS; however, the clinical outcomes of patients who experience this are equivalent to
those who do not.10 The second is that both leads ended up with
defects requiring replacement. Since we had several months of
GPi system stimulation with normal functioning prior to noting
the increased impedance values, we believe there was adequate
time to evaluate its effectiveness, or lack thereof.
In making strong recommendations, we are limited by the rarity of the condition, leaving us to draw conclusions from the experience of a case series. However, it seems evident that DBS is
safe and efficacious in treating CS-associated movement disorders with multiple viable targets. Target selection should be driven
by the clinical phenotype, with tremor predominance responding better to VIM stimulation, while dystonia predominance responds better to GPi stimulation.
Ethics Statement
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Supplementary Video Legends
Video 1. Patient performing the finger-to-nose task 4 weeks after bilateral
VIM implant prior to the initial activation of the deep brain stimulation
(DBS) system (segment 1) and then after initial system activation (segment
2), demonstrating improved tremor control with DBS stimulation.
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The online-only Data Supplement is available with this article at https://
doi.org/10.14802/jmd.21005.
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Supplementary Figure 1. Neuroimaging characteristics of Cockayne syndrome. Neuroimaging characteristics of Cockayne syndrome, including basal ganglia calcifications shown on the CT of the head (A), white matter abnormalities on T2 fluid-attenuated inversion recovery
(B), basal ganglia susceptibility on susceptibility weighted imaging (C), and cerebral atrophy with predominant white matter loss on T2 (D)
were noted in our patient.

